FX-909 is a covalent peroxisome proliferator-activated receptor gamma (PPARG) inverse agonist. FX-909 may be utilized in tumor-related research.

Physicochemical Properties

Molecular Formula	C17H10F2N2O3S
Molecular Weight	360.334709644318
Exact Mass	360.038
CAS #	2924573-90-8
PubChem CID	167993670
Appearance	White to off-white solid powder
LogP	2.4
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	2
Heavy Atom Count	25
Complexity	737
Defined Atom Stereocenter Count	0
SMILES	C1(F)C=C2C(=C(F)C=1)C(=O)C=C(C1=C(C=CC(C#N)=C1)S(=O)(=O)C)N2
InChi Key	RBUBBZVQPHSZEZ-UHFFFAOYSA-N
InChi Code	InChI=1S/C17H10F2N2O3S/c1-25(23,24)16-3-2-9(8-20)4-11(16)13-7-15(22)17-12(19)5-10(18)6-14(17)21-13/h2-7H,1H3,(H,21,22)
Chemical Name	3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	PPARγ
ln Vivo	In a UMUC9 UC xenograft mouse model, FX-909 (0.03-1 mg/kg; BID for 21 days) has anti-cancer properties [1].
References	[1]. Development of a surrogate tissue pharmacodynamic (PD) assay for clinical use with FX-909, a novel inhibitor of the urothelial luminal lineage transcription factor peroxisome proliferator-activated receptor gamma (PPARG). Cancer Research, 2023, 83(7_Supplement): 2802-2802.
Additional Infomation	PPAR Gamma Inhibitor FX-909 is an orally available inverse agonist and inhibitor of the transcription factor (TF) peroxisome proliferator-activated receptor gamma (PPAR gamma; PPARG), with potential antineoplastic activity. Upon oral administration, PPARG inhibitor FX-909 selectively targets and covalently binds to a region of PPARG that is sequestered from the mutation site. The binding promotes a repressive conformation of PPARG and inhibits the activity of PPARG. This inhibits both basal- and ligand-activated transcription by PPARG and prevents PPARG-mediated transcription of target genes, such as FABP4/Fabp4, AGT/Agt, IVT/Ivd and ARG1/Arg1. This may inhibit proliferation in PPARG-overactivated tumor cells. PPARG, a nuclear receptor, is genetically altered, including amplification, missense mutations, and fusions, in certain tumor cells commonly associated with the luminal lineage subtype.

Solubility Data

Solubility (In Vitro)

DMSO: 100 mg/mL (277.52 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (6.94 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.7752 mL	13.8762 mL	27.7523 mL
	5 mM	0.5550 mL	2.7752 mL	5.5505 mL
	10 mM	0.2775 mL	1.3876 mL	2.7752 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.